Recently, a difference has been shown in pCR rate after NAC in breast cancer by the intrinsic subtypes; patients with HER2-enriched or triple-negative tumors are more likely to achieve pCR than those with a luminal-type tumor [32, 33]. This evidence concerns the gene ERBB2 and breast cancer.